Edoxaban

• Edoxaban, from Daiichi Sankyo, is in Phase 3 development, with pivotal trial expected to completed in 2012.

Study Gives Lift to Drug That Cuts Stroke Risk Ron Winslow 2011

FDA expected by the end of 2011 Edoxaban Daiichi Sankyo In phase 3, with pivotal trial expected to completed in 2012 Betrixaban Portola Pharmaceuticals Inc. Completed Phase 2 or mid-stage trials.

Study Gives Lift to Drug That Cuts Stroke Risk Ron Winslow 2011

Daiichi Sankyo Japanese Application Filed For Blood-Clot Treatment Daiichi Sankyo Co. said it has filed a new drug application in Japan for Edoxaban, an important step in commercializing the treatment to prevent blood clots.

Corporate Watch 2010

Goldman Sachs analyst Steve Chesney said that Edoxaban and influenza treatment Laninamivir, for which Daiichi filed a new drug application in Japan in February, have the potential to generate over $1 billion a year.

Daiichi Files For Approval Of Blood Clot Drug Kazuhiro Shimamura 2010

Daiichi Sankyo is also conducting clinical trials on Edoxaban for people at risk of developing clots in veins due to blood coagulation or in arteries due to irregular heartbeats.

Corporate Watch 2010

Profitability is generally high for products like Edoxaban which are developed without partners.

Daiichi Files For Approval Of Blood Clot Drug Kazuhiro Shimamura 2010

Daiichi Sankyo is also conducting clinical trials on Edoxaban for people at risk of developing clots in veins due to blood coagulation or in arteries due to irregular heartbeats.

Corporate Watch 2010

When Daiichi Sankyo eventually develops Edoxaban for patients with irregular heartbeats, it will be able to tap into the lucrative market for atrial fibrillation treatment which analysts estimate exceeds $15 billion a year globally.

Daiichi Files For Approval Of Blood Clot Drug Kazuhiro Shimamura 2010

When Daiichi Sankyo eventually develops Edoxaban for patients with irregular heartbeats, it would be able to tap into the lucrative market for atrial-fibrillation treatment, which analysts estimate exceeds $15 billion a year globally.

Corporate Watch 2010

Daiichi is also conducting clinical trials on Edoxaban for people at risk of developing clots in veins due to blood coagulation or in arteries due to irregular heartbeats.

Daiichi Files For Approval Of Blood Clot Drug Kazuhiro Shimamura 2010